- Home
- PGEN vs LBTYA Comparison
PGEN vs LBTYA Comparison
Compare PGEN & LBTYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | LBTYA |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2013 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PGEN | LBTYA |
|---|---|---|
| Price | $7.02 | $7.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $13.65 | ★ $14.24 |
| AVG Volume (30 Days) | ★ 4.5M | 4.2M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.03 | ★ 0.96 |
| Revenue | $230,981,000.00 | ★ $11,541,500,000.00 |
| Revenue This Year | $2,335.22 | $37.63 |
| Revenue Next Year | $85.34 | $23.45 |
| P/E Ratio | $223.17 | ★ $8.04 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.04 | $7.36 |
| 52 Week High | $8.98 | $13.52 |
Technical Indicators
Market Signals| Indicator | PGEN | LBTYA |
|---|---|---|
| Relative Strength Index (RSI) | 50.05 | 34.84 |
| Support Level | $6.57 | N/A |
| Resistance Level | $7.44 | $10.97 |
| Average True Range (ATR) | 0.42 | 0.33 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 55.14 | 28.30 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About LBTYA Liberty Global Ltd.
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.